Media advisory: Mayo Clinic study finds infliximab ‘safe and beneficial’ for Crohn’s disease

Video Feed: A video feed, including sound bites from the study’s principal investigator, a patient interview and b-roll will be fed via satellite at 3 p.m. CST on Tues., March 13, 2001.

Media Advisory

WHAT: Mayo Clinic Study Finds Infliximab ‘Safe and Beneficial’ for Crohn’s disease

A new drug for treating Crohn’s disease (CD), infliximab, (Remicade, Centocor Inc.), is safe and beneficial for patients who have not gotten relief from other medications, according to findings of a Mayo Clinic study published in the March issue of the American Journal of Gastroenterology. Of the first 100 Mayo Clinic patients to receive infliximab infusions, 72 experienced a positive response.

WHEN: Tuesday, March 13, 2001

Eastern Central Test: 16:00-16:05 (EST) 15:00-15:05 (CST) Program: 16:05-16:30 15:05-15:30

Satellite Coordinates Ku-Band / C-Band Satellite: Galaxy 11 / Galaxy 4 Transponder: 16 (V) / 12 (V) Channel: 16 / 12 Downlink Frequency: 12020 MHz / 3940 MHz Audio: 6.2 or 6.8 MHz / 6.2 or 6.8 MHz Longitude: 91° W / 99° W

Technical Questions Prior to Broadcast ONLY: 507-284-5964 (Mayo Clinic Video Communications) Satellite Technical Difficulties: 800-608-3663 (Strategic Television)